Navigation Links
Amgen And AstraZeneca Highlight Data To Be Presented At European League Against Rheumatism Annual Meeting
Date:6/12/2013

THOUSAND OAKS, Calif. and GAITHERSBURG, Md., June 12, 2013 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and AstraZeneca (AZN), with its biologics research and development arm MedImmune, today announced that they will present data from a Phase 2 study evaluating brodalumab, a human monoclonal antibody targeting the IL-17 receptor, being investigated for the treatment of psoriatic arthritis at the 2013 European League Against Rheumatism (EULAR) Annual Meeting in Madrid, June 12-15, 2013. 

"The brodalumab data being presented at EULAR demonstrate a positive benefit-risk profile for patients with psoriatic arthritis," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. "We are encouraged by these data as we continue to explore brodalumab for its potential to treat patients with inflammatory disease including psoriatic arthritis."

Based on the Phase 2 results, the companies intend to advance brodalumab into Phase 3 clinical studies for the treatment of psoriatic arthritis in 2014.

"This brodalumab data marks a positive step forward for patients with psoriatic arthritis," said Dr. Bahija Jallal, executive vice president, MedImmune.  "We look forward to working with Amgen to further evaluate this novel therapy in psoriatic arthritis and potentially other chronic immune-mediated diseases."

ABSTRACT OF INTEREST:

Brodalumab Abstract at EULAR:

  • Efficacy of Brodalumab, an Anti-IL-17R Antibody, in Subjects with Psoriatic Arthritis
    Abstract No. OP0103, Oral Presentation, Thursday, June 13, 10:20 a.m. CET, N117

Abstracts are currently available on the EULAR website at www.eular.org.

About Brodal
'/>"/>

SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Amgen and FDA Agree to Modify Nplate® (Romiplostim) Risk Evaluation and Mitigation Strategy
2. Amgen Presents Final Results from the Largest Phase 3 Open-Label Study Assessing the Safety and Efficacy of Nplate® (Romiplostim)
3. Amgen Announces 2012 First Quarter Dividend
4. Kevin Sharer, Amgen Chairman and CEO, Announces Plan to Retire With Robert Bradway to Become CEO on May 23, 2012; Sharer Will Continue as Chairman of the Board Until End of 2012
5. Amgen to Present at the 30th Annual J.P. Morgan Global Healthcare Conference
6. Amgen Announces Webcast of 2011 Fourth Quarter and Full Year Financial Results
7. Amgen to Acquire Micromet
8. Amgen to Present at the Leerink Swann Global Healthcare Conference
9. Amgen Announces 2012 Third Quarter Dividend
10. Amgen Names Ray Jordan Senior Vice President, Corporate Affairs
11. Amgen To Present At The 24th Annual Piper Jaffray Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... the first time, chemists have succeeded in measuring vibrational ... resolution. The study reveals how vibration of a single ... , The study was performed at the University ... the University of Jyvskyl works as a visiting fellow ... the study. The second team was lead by Professor ...
(Date:8/20/2014)... Mass. , Aug. 20, 2014  Decision Resources Group finds ... , Russia , India ... $1.6 billion in 2013, roughly equal to the size of ... however, the BRIC market will experience much faster growth as a ... aging population. Other key findings from Decision Resources Group,s ...
(Date:8/20/2014)... Not long ago, it was more ... performed late in the development cycle – even after ... trends suggest that, like many things GxP, expectations for ... years, multiple drug sponsors have been required by authorities ... during phase I/II. It’s not only clinical trial material ...
(Date:8/20/2014)... WriteResult®, a leading provider of Electronic Patient ... its myPROpad™ ePRO tablet with the addition of a ... most widely used and well-respected Patient Reported Outcome (PRO) ... is used during clinical trials and in other health ... used to demonstrate Health-Related Quality of Life outcomes (HRQoL) ...
Breaking Biology Technology:Seeing a molecule breathe 2BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 2BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 3Are Extractable and Leachables going Phase-Appropriate? New Webinar Hosted by Xtalks 2EQ-5D™ Assessment Now Available for iPad 2
... 14 For 88 percent of,companies, front-line and ... cover a variety of development skills but focus,strongly ... Yet only half of executive-level sales leaders ... leadership development and,training, according to a member-driven research ...
... April 14 eResearchTechnology,Inc. (eRT), (Nasdaq: ... today their,alliance to provide integrated Cardiac Safety ... worldwide., eResearchTechnology is a leading provider ... other services,to the pharmaceutical, biotechnology, medical device, ...
... Corporation,(Pink Sheets: PHCP) (the "Company") clarified today that ... connection with,market transactions and are a valid representation ... This clarification was issued in response to,information from ... firms,will not negotiate Phlo common stock certificates issued ...
Cached Biology Technology:Developing Sales Leaders: Benchmarks Reveal Tactics that Will Propel Your Business 2eResearchTechnology, Inc. and nSpire Health, Inc. Form Alliance to Deliver Integrated Cardiac Safety and Pulmonary Clinical Trial Services 2eResearchTechnology, Inc. and nSpire Health, Inc. Form Alliance to Deliver Integrated Cardiac Safety and Pulmonary Clinical Trial Services 3Phlo Clarifies That Pre-Reverse Split Certificates Are Negotiable in Market Transactions 2
(Date:8/21/2014)... 2014 , WHERE: , San Diego Convention ... 92101 , WHAT: , Invited and platform ... research in human genetics. Examples of sessions include: ... rare genetic variants in health and disease, the ... sensitivity (Saturday, Oct. 18, 5:30-7:30 pm) , Crowdsourced ...
(Date:8/21/2014)... from North Carolina State University have developed a novel ... model has applications for creating new materials as well ... "Our new technique allows us to model much larger ... much more quickly," says Nan Li, lead author of ... in NC State,s Department of Materials Science and Engineering. ...
(Date:8/20/2014)... Knoxville, research finds life can persist in a cold, ... of a team that examined waters and sediments from ... and found the extreme environment supports microbial ecosystems. ... and her colleagues has implications for life in other ... system. The findings are published in the current edition ...
Breaking Biology News(10 mins):American Society of Human Genetics 2014 Annual Meeting 2Researchers develop models to study polyelectrolytes, including DNA and RNA 2University of Tennessee research uncovers subglacial life beneath Antarctic ice sheet 2
... are thrown away in the European Union each year. However, ... The brown skin and external layers are rich in fibre ... fructans. All of these substances are beneficial to health. ... line with the growing demand for these bulbs. More than ...
... A recent multi-center study determined that women with ... seizures during anovulatory cyclesmenstrual cycles where an egg is ... the study publishing today in Epilepsia , a ... steroids may play a role in GTCS occurrence. ...
... (UPC) have developed a method for evaluating the vulnerability ... method, which has been applied on the Catalan coastline, ... high rate of vulnerability to flooding, while 20% are ... no tool for evaluating coastal storm vulnerability that could ...
Cached Biology News:Dry onion skin has a use 2Greater seizure frequency seen in women with epilepsy during anovulatory cycle 2One-third of central Catalan coast is very vulnerable to storm impact 2
Collected from 8-12 week-old New Zealand or Californian rabbits.,Supplied in lyophilized form....
Silica bead method is an economic method of DNA extraction from agarose...
BD IMag Anti-Mouse CD90.2 (Thy1.2) Particles-MSC 2 x 109 cells...
AgarPlaque Plus Agarose 50 grams...
Biology Products: